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Histone deacetylases (HDACs) have been shown to be required for basal or inducible transcription at a variety of genes by poorly
understood mechanisms. We demonstrated previously that HDAC inhibition rapidly repressed transcription from the mouse
mammary tumor virus (MMTV) promoter by a mechanism that does not require the binding of upstream transcription factors.
In the current study, we ﬁnd that HDACs work through the core promoter sequences of MMTV as well as those of several cellular
genes to facilitate transcriptional initiation through deacetylation of nonhistoneproteins.
1.Introduction
Histone deacetylases (HDACs) comprise a large and varied
family of proteins which are divided into four classes
based on structural homologies [1]. Interest in their role
in development, physiology, and cell biology has been
intensiﬁed by the development of small molecule inhibitors
of class I (HDACs 1–3, 8) and class II (HDACs 4–7, 10)
family members as anticancer drugs. Two such inhibitors,
Vorinostat and Romidepsin, are now approved for treatment
of advanced cutaneous T-cell lymphoma and many more
are being evaluated in clinical trials [2]. These drugs are
also being considered for use in other diseases including car-
diovascular, neurodegenerative, and inﬂammatory disorders
[3–5]. In spite of their current and potential clinical use,
the precise roles of HDACs in regulating cellular processes
through proteinacetylation are largely unknown. HDACs are
thought to control cell growth and survival through both
transcriptional and nontranscriptional pathways that may
be partially speciﬁc to cell type (reviewed in [6]). Currently
our lack of knowledge about the general and cell-speciﬁc
functions of HDACs limits our ability to predict whether
particular tumors will respond to HDAC inhibitors and
which other therapeutics might work synergistically with
these drugs in treating various cancers.
Long-standing models of the role of acetylation in
transcription generallycasthistoneacetyltransferases (HATs)
as coactivators and HDACs as corepressors [7]. This is based
on the positive relationship between histone acetylation
and transcription and the fact that many transcriptional
activatorsrecruitHATstotargetpromoters.Incontrast,there
is a negative correlation between histone hypoacetylation
and transcription, and HDACs are often found in complexes
that work to repress transcription. This model, however, is
inadequatetoexplainalltherolesofHDACsintranscription.
Expression proﬁling of cells treated with HDAC inhibitors
[8–14] shows that genes are both activated and repressed
by these drugs. Gene repression is observed even within 2h
of treatment when eﬀects on transcription are likely to be
the direct result of HDAC inhibition rather than secondary
eﬀects dependent on prior changes in gene expression. In
addition, studies of individual genes have demonstrated
direct repressive transcriptional eﬀects of HDAC inhibitors
or knockdown of particular HDACs (reviewed in [15, 16]).
Furthermore, transcriptional activators such as glucocorti-
coid receptor (GR) and STATs 1, 2, and 5 have been shown2 Journal of Biomedicine and Biotechnology
to interact with HDACs at target genes to facilitate tran-
scription [17–20]. Finally, a recent genomewide mapping
study showed that in addition to HATs, HDACs are enriched
at the promoters of active genes and are recruited along
with HATs to transcriptionally inducible genes [21]. Taken
together, this accumulated evidence indicates that HDACs
serve an important role in the activation of transcription
and/or maintenance of the activated state. However, the
mechanisms by which HDACs facilitate transcription are
poorly understood.
One example of a promoter that is repressed by HDAC
inhibitors [22–26]o rH D A Ck n o c k d o w n[ 17]i st h a to f
the mouse mammary tumor virus (MMTV), a well-studied
model system for glucocorticoid receptor- (GR-) mediated
activation of transcription. Initially, it was reported that
transcriptional activation of this promoter by glucocorti-
coids was signiﬁcantly impaired in the presence of HDAC
inhibitors [23]. Later, we and others showed that basal
MMTVtranscriptionwasalsorepressed[22,24].Wedemon-
strated that this repression was very rapid and potent but
occurred independently of changes in histone acetylation,
chromatin remodeling, or chromatin structure [22]. Our
analysis of the sequences required for repression showed
that sequences upstream of the TATA box were dispensable.
We concluded that HDACs facilitated MMTV transcription
through nonhistone proteins which are essential for eﬃcient
basaltranscription. Morerecently,Qiuetal.[17]showedthat
HDAC1 can be found in GR complexes and is associated
with the MMTV promoter in the presence and absence
of glucocorticoids. In addition, they showed that siRNA-
mediated knockdown of HDAC1 impaired the ability of GR
to activate the promoter. Together these data make a strong
case that HDAC activity is required to facilitate both basal
and activated transcription at the MMTV promoter.
In the current study, we have investigated the mechanism
by which HDAC inhibition impairs basal transcription.
Key to our ﬁndings was the development of an in vitro
transcription system that recapitulates repression of MMTV
transcription due to inhibition of HDAC activity. Surpris-
ingly we ﬁnd that the repression is conferred through the
MMTV core promoter and involves impaired transcriptional
initiation. Our results have revealed a novel role of HDAC
activity in promoting transcription.
2.Materialsand Methods
2.1. Cell Culture. Cell line 1470.2 is derived from C127i
mouse mammary adenocarcinoma cells and contains stably
replicating copies of a transcription unit consisting of the
MMTV long terminal repeat (LTR) driving expression of the
chloramphenicol acetyltransferase (CAT) gene. Both 1470.2
andHelacellsweremaintained inDulbecco’sMediaEssential
Medium (DMEM), containing 10% fetal bovine serum.
2.2. Plasmids. pMluc and pMTV(TATA/+100)luc have been
previously described [22]. pMTV(TATA-DPE)luc contains
MMTV LTR sequences from −40 to +32bp. pMTV(TATA-
Inr)luc contains MMTV LTR sequences from −40 to +4bp.
BothareclonedintopXP1,apromoterlessluciferasereporter
construct [27]. The luciferase constructs containing core
promoters from cytomegalovirus (CMV), c-fos, interleukin
4 (IL4), and carbonic anhydrase 2 (CA2) were generated
by cloning annealed oligonucleotides with sequences from
t h eT A T Ab o xt oI n re l e m e n tf o re a c hg e n ei n t op X P 1 .
pAdML was a gift from Dr. Gordon Hager (NCI, NIH,
Bethesda, MD). It contains a 190bp G-free cassette 3  to
the Adenovirus Major Late (AdML) promoter. pMTV-InrA-
G, the MMTV template used for in vitro transcription,
was constructed by subcloning annealed oligonucleotides
containing MMTV LTR sequences (−39 to +5bp) just 5  of
the400bpG-free cassette ofpC2AT19 (a gift from Dr. Robert
Roeder, Rockefeller University). The transcription start site
of the MMTV promoter is a G nucleotide. It was modiﬁed to
an A in pMTV-InrA-G for use with the G-free cassette. This
modiﬁcation did not aﬀect core promoter activity under any
of the conditions tested in this study (data not shown).
2.3. Transfection Assays. DNA was transiently transfected
into HeLa cells using the calcium phosphate method accord-
ing to the manufacturer’s protocol (Invitrogen, Carlsbad,
CA). Two days after transfection, cells were treated and
harvested as described previously [22]. Cell line 1470.2 was
transfected by electroporation as described [22]. Treatment
and harvest was carried out 1 day after transfection. Lysates
from both cell lines were assayed for protein concentration
and luciferase activity. Luciferase activities were normalized
to protein concentration for each sample.
2.4. Chromatin Immunoprecipitation (ChIP) Assay. The
ChIP assay was performed as described by Magklara and
Smith[28]with slight modiﬁcation. Brieﬂy,1470.2cellswere
grown to 95% conﬂuencyon 150mm platesand treated with
50ng/ml TSAor 100nM dexamethasone (Dex) for 15, 30, or
60 minutes. The cells were ﬁxed with 1% formaldehyde for
10 minutes at 37◦C and neutralized with 0.125M glycine.
After collection of cells by scraping, they were washed 3X
with cold PBS and incubated with lysis buﬀer (1% SDS,
10mM EDTA, 50mM TrisHCl, pH8.0) for 10 minutes on
ice. After centrifugation cells were resuspended in 1.5ml
lysis buﬀer and sonicated. Chromatin was precleared with a
mixture of protein Aand G agarose beads containing salmon
sperm DNA. The supernatants were then incubated with 3
to 5μg 8WG16 RNA polymerase II antibody (Covance) for
16h at 4◦C. Protein A and G agarose beads were added and
incubation continued for 2h. Subsequently,chromatin-bead
c o m p l e x e sw e r ew a s h e do n c ee a c hw i t hl o ws a l tb u ﬀer(0.1%
SDS,1% Triton-X100,2mM EDTA,20mM Tri-HCl,pH8.0,
50mM NaCl), high salt buﬀer (0.1% SDS, 1% Triton-X100,
2mM EDTA, 20mM Tri-HCl, pH 8.0, 500mM NaCl),
and lithium chloride buﬀer (250mM LiCl, 1% NP40, 1%
deoxycholate, 1mM EDTA, 10mM Tris-HCl) and twice
with TE buﬀer. All buﬀers contained protease inhibitors.
Bound chromatin was eluted successively with 1.5% SDS
buﬀer (1.5% SDS, 0.1M NaHCO3) and 0.5% SDS buﬀer
(0.5% SDS, 0.1M NaHCO3). Crosslinks were reversed by
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and 10μg RNase A. Protein was digested at 45◦Cf o r2hi n
the presence of 10mM EDTA, 40mM Tris-HCl pH6.5, and
20μg proteinase K. DNA was extracted twice with phenol-
chloroform-isoamyl alcohol andp r e c i p i t a t e dw i t he t h a n o l
in the presence of glycogen. Detection of MMTV sequences
was carried out by PCR analysis using the following
primers: MMTV promoter/5 transcribed region—Forward-
5 TTTCCATACCAAGGAGGGGACAGTG3 ,Reverse-5  CT-
TACTTAAGCCTTGGGAACCGCAA3 ,C A Tc o d i n gr e g i o n
(CDS)—Forward-5  CCGTTTTCACCATGGGCAAA3 ,
Reverse-5  AAGCATTCTGCCGACATGGA3 .Ineachexper -
iment, cycle number was empirically adjusted so that ampli-
ﬁcation of the desired sequences was in the linear range.
Generally, cycle number varied between 22 and 28 cycles.
2.5. HeLa Nuclear Extract Preparation. Hela S3 cell pellets
were purchased from the National Cell Culture Center.
Cultures of Hela S3 cells (5 liters at 0.5 × 106 cell/ml) were
treated with or without TSA (50ng/ml) for 2h. Cells were
pelletedandﬂash frozenpriortoovernightshipping.Nuclear
extracts were prepared by the method ofKusk et al. [29]wi t h
modiﬁcation. All procedures were conducted at 4◦Ca n da l l
buﬀers used in the extraction procedure contained 500μM
AEBSF, 150nM aprotinin, 1μM E-64, 0.5mM EDTA, and
1μM leupeptin. TSA (50ng/ml) was included in all buﬀers
used for generation of nuclear extracts from TSA-treated
cells. Upon receiving the cells, they were thawed and washed
once with ice-cold PBS and resuspended in ﬁve packed cell
volumes (PCV) of HB1 (10mM HEPES, pH 7.9, 10mM
KCl, 0.1mM EDTA, 0.75mM spermidine, and 0.15mM
spermine). After incubation on ice for 10 minutes, the cells
were centrifuged and resuspended in two PCV HB1. The
cells were subsequently lysed by Dounce homogenization.
One-tenth volume of HB2 (67.5% sucrose in HB1) was
added, and the homogenates were centrifuged at 16,000×g
for 2 minutes. The nuclear pellets were resuspended in NLB
(20mM HEPES pH 7.6, 100mM KCl, 12.5mM MgCl2, 20%
glycerol,0.2mMEGTA, 0.2mMEDTA,and2mMDTT)and
rotated for 30 minutes. The nuclear lysates were centrifuged
(150,000×g, 90 minutes), and the pellets were mixed with
0.33g solid ammonium sulfate/ml and resuspended in NLB.
After rotation for 20 minutes, precipitated proteins were
collected by centrifugation (85,000×g, 20 minutes) and
resuspended gradually in approximately 1ml dialysis buﬀer
(20mM HEPES pH 7.6, 100mM KCl, 12.5mM MgCl2,
20% glycerol, 0.2mM EGTA, 0.2mM EDTA, and 2mM
DTT). The extracts were dialyzed twice for 2h in 1 liter of
dialysisbuﬀer.Supernatantwas collectedaftercentrifugation
(18,000×g, 20 minutes), aliquoted, and stored at −80◦C.
2.6. In Vitro Transcription Assay. The assay was performed
as described by Kusk et al. [29] with minor modiﬁcation.
The ratio of nuclear extract protein to DNA was optimized
for each set of nuclear extracts. In general, approximately
60μg extract protein was used with 1200–1500ng DNA
template per reaction. Brieﬂy, nuclear extract was incubated
at 30◦C for 60 minutes with DNA template in a 30μl
reaction mixture containing 20mM HEPES, pH7.9, 60mM
KCl, 2mM DTT, 5mM creatine phosphate, 1mM 3 -O-
methyGTP, 0.5mM ATP, 0.5mM CTP, 20μMU T P ,5 m M
MgCl2,1 0 μCi [α-32P]UTP (400Ci/mmol), 10% glycerol,
and 10URNase T1. The reaction was terminated by addition
of 300μl of Stop Solution (20mM EDTA, 0.2M NaCl, 1%
SDS,and 10μg tRNA). RNA transcripts were extracted twice
withphenol/chloroform/isoamylalcoholfollowedbyethanol
precipitation. The transcripts were resuspended in denatur-
ing loading dye, incubated at 95◦Cf o r3 - 4m i n u t e s ,a n d
separated in 6% denaturing polyacrylamide gels (Sequagel,
National Diagnostics). Gels were dried and exposed to
phosphorimaging screens. Radiolabeled transcripts were
visualized with a Storm phosphoimager (Molecular Dynam-
ics, Sunnyvale, CA).
For competition assays, nuclear extracts were preincu-
bated with diﬀerent amounts of the pAdML template for
30 minutes at 30◦C. Subsequently, the in vitro transcription
reaction mixture containing NTPs and the MMTV template
was added, and the transcription was allowed to proceed for
30 minutes at 30◦C. For analysis of de novo transcription,
nuclearextractswere incubatedwith eitherMMTV orAdML
template for 10 minutes at 30◦C after which in vitro reaction
mixture was added. Approximately 30 seconds later, water
or Sarkosyl (0.05% ﬁnal concentration) was added, and
transcription was allowed to proceed for 30min before
the reaction was stopped and transcript production was
analyzed.
2.7. HDAC Assay. HDAC assays were carried out as
described [17]. Nuclear extract protein (20μg) was diluted
in assay buﬀer (20mM Tris HCl, 150mM NaCl, 0.5mM
EDTA, and 5% glycerol) in the presence or absence of TSA
(50ng/ml). The mixture was incubated for 30min at 30◦C
to allow for HDAC inhibition. Subsequently, 3H-acetylated
histones prepared from sodium butyrate-treated Hela cells
were added, and incubation continued for an additional
30min. The reaction was stopped with denaturing buﬀer
(1.44M HCl and 0.24M acetic acid). Tritiated acetyl groups
released by HDAC activity were extracted using ethyl acetate.
Released cpms were measured by scintillation counting.
3.Results
3.1. HDAC Activity Is Required for Transcription from TATA
Box Containing Core Promoters. O u rp r e v i o u ss t u d ys h o w e d
that the repression of MMTV transcription by HDAC
inhibitors did not require sequences upstream of the TATA
box [22]. Repression was conferred through a region of
the promoter that extended from the TATA box to 100bp
downstream of the transcription start site. In the current
study, we further dissected the sequences required for
repression. In particular, we were interested in determining
the role of the core promoter, a region roughly deﬁned as
−40 to +40bp relative to the start site of transcription (TSS).
As reviewed in [30] ,t h ec o r ep r o m o t e ro fag e n ei sm a d e
up of a series of elements which are not common to every
core promoter but are generally found in subsets, depending
on the particular gene. These include the upstream and4 Journal of Biomedicine and Biotechnology
downstream TFIIB recognition elements (BREs), the TATA
box, and the initiator element (Inr), all of which are located
upstream of the TSS with the exception of the Inr, which is
located around the TSS. Some core promoters also contain
elements downstream of the TSS including the downstream
promoter element (DPE), the motif ten element (MTE), and
the downstream core element (DCE).
The MMTV promoter contains a functional TATA box
and initiator [31] but does not have BRE sequences. Down-
streamoftheTSSthereisasequencethathassomehomology
to the DPE consensus. To determine whether any of these
elements confer repression mediated by HDAC inhibition,
a series of luciferase reporter constructs were generated that
contain various fragments of the MMTV promoter as shown
in Figure 1(a). These constructs were transfected into Hela
cells or 1470.2 cells, which were derived from the C127i
mouse mammary adenocarcinoma cell line as described in
Section 2. Consistent with our previous study, repression by
TSAis notdependentoncisacting sequencesupstream ofthe
TATA box (compare pMluc with pMTV(TATA/+100)luc).
Repression is also conferred by a fragment extending
from the TATA box to the sequence resembling the DPE
[pMTV(TATA-DPE)luc]. However, the DPE-like sequence
is not required because a construct containing sequences
between the TATA box and Inr [pMTV(TATA-Inr)luc] is
suﬃcient to confer TSA-induced repression in both cell
lines. Thus, we conclude that the repression of MMTV
transcription mediated by HDAC inhibition is dependent
solely on its functional core promoter elements.
In our previous study, we also showed that minimal
promoter sequences from other viral and cellular genes were
repressed by TSA treatment [22]. It is therefore possible that
basal transcription of other core promoters is also sensitive
to HDAC inhibition. Reporter constructs containing the
analogous region from several viral and cellular TATA box-
containing promoters were generated and transfected into
Hela or 1470.2 cells. The results (Figure 2) show that TSA
causes repression of core promoters from all genes tested,
indicating that transcription dependent on the TATA to Inr
region is generally sensitive to HDAC inhibition.
3.2.HDACActivityIsRequiredforTranscriptional Initiationat
theMMTVPromoter. ThesensitivityoftheMMTVcorepro-
moter to HDAC activity could be due to a role for HDACs in
regulation of either transcriptional initiation or elongation.
Inthecaseoftheformer, therecruitmentofRNApolymerase
II (RNA pol II) may be impaired by HDAC inhibition.
In the case of the latter, polymerase recruitment may be
unaﬀected, but its ability to clear the 5  transcribed region
(ﬁrst 100bp) may be impaired due to pausing or stalling.
To distinguish between these possibilities, we performed
chromatin immunoprecipitation (ChIP) assays to measure
the association of RNA pol II with the core promoter/5 
transcribed region. If transcriptional initiation is impaired
by HDAC inhibition, polymerase association with the core
promoter may decrease due to a defect in polymerase
recruitment. If HDAC activity is required to prevent pausing
or stalling of polymerase, the association of RNA pol II with
the 5  transcribed region would be unchanged or somewhat
increased as stalled polymerase accumulates. In the ChIP
assays, we used an antibody that preferentially binds to
RNA pol II with a hypophosphorylated C-terminal domain
(CTD). This antibody has been shown to recognize both
initiating as well as 5  pausedpolymerase [32,33]whic hdoes
not contain a highly phosphorylated CTD because serine 2
phosphorylation has not yet occurred [34].
Cell line 1470.2 contains stably replicating copies of
a transcription unit consisting of the full-length MMTV
LTR/promoterdrivingtheexpressionofthechloramphenicol
acetyltransferase (CAT) reporter gene. Basal and activated
expression of the MMTV-CAT gene in this cell line has been
previously shown to be inhibited by TSA treatment [22].
Cells were treated with TSA for various times shown in
Figure 3. As a positive control for RNA pol II association
withtheMMTV promoter,weincludedchromatinfromcells
treated with the synthetic glucocorticoid, Dexamethasone
(Dex), which induces transcription from the promoter. As
expected [35], Dex treatment rapidly but transiently induces
recruitment of RNA pol II to the MMTV promoter (Fig-
ure3(a),leftpanel).Thereisnoassociationwithdownstream
sequencesin the CAT coding region (CATCDS)that are well
separated from the core promoter region, thus conﬁrming
that the antibody preferentially recognizes the polymerase in
its initiating rather than its hyperphosphorylated elongating
form.
InthepresenceofTSA,theassociationofRNApolIIwith
the core promoter/5  transcribed region clearly decreases
over a time frame of 60 minutes (Figure 3(a),r i g h tp a n e l ) .
A quantitative representation of RNA pol II association data
from 2 to 3 experiments with TSA is shown in Figure 3(b).
By 60 minutes of TSA treatment, there is a 60% loss of
polymerase.Thisisingoodagreementwiththemagnitudeof
repression observed in the transfection experiments shown
in Figure 1. In addition, both the kinetics and magnitude of
TSA-induceddecrease inpromoter association ofRNApol II
are highly consistentwith changes in therateoftranscription
from the MMTV promoter as measured by nuclear run-on
in our previous study, in which we observed a 60–70% drop
in transcription from the MMTV-CAT gene within 30–60
minutesofTSAtreatment[22].Fromthesedata,weconclude
that HDACactivity is requiredin some way for eﬃcientRNA
pol II recruitment and transcriptional initiation.
3.3. Development of an In Vitro Transcription System to
Study the Role of HDACs in Transcriptional Initiation. Our
previous study showed that HDAC inhibition does not lead
to changes in chromatin structure, chromatin remodeling,
or large increases in histone acetylation at the MMTV
promoter [22], leading us to hypothesize that HDACs
play a role in regulating the interactions or functions of
nonhistone proteins essential for transcription from this
promoter context. Thus, the mechanisms by which HDAC
activity impact core promoter activity could be precisely
deﬁned by in vitro transcription assays, which allow a level
of experimental control not possible in cell-based assays. To
develop such an assay, we adopted the methods of Kusk et al.Journal of Biomedicine and Biotechnology 5
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Figure 1: The MMTV core promoter confers transcriptional repression by the HDAC inhibitor, TSA. Various luciferase reporter constructs
containing fragments of the MMTV promoter shown in (a) were transiently transfected into Hela or 1470.2 cells and treated with or
without TSA (50ng/ml) for 6h prior to harvest. Cell lysates were assayed for luciferase activity, and these values were normalized to protein
concentrationforeachsample.Normalizedvaluesforuntreated (control)sampleswere setto1,andvaluesfortreated sampleswere expressed
asafraction.Statisticalanalysiswasperformed onresults from3to7 independent experiments.Results fromHelaand1470.2cells areshown
in (b) and (c), respectively. Error bars represent SEM.
[29] who had measured MMTV core promoter function in
vitrousing templateswith G-free cassettes [36].Ourgoalwas
to compare transcription in nuclear extracts generated from
cells treated with TSA to those generated from untreated
cells to determine whether the repression observed in cell-
based assays could be recapitulated in vitro. Because they
can be easily grown in large quantities, we turned to Hela
S3 cells to generate nuclear extracts by the strategy outlined
in Figure 4(a). In the case of extracts made from cells treated
with TSA, we maintained TSA in all buﬀers during extract
preparation to prevent HDACs from becoming reactivated.
We chose to compare transcription of two promoters:
MMTV and adenovirus major late (AdML). We designed
an MMTV template containing the core promoter from
the TATA box to the Inr upstream of a G-free cassette of
approximately 400bp (Figure 4(b)). The AdML template
contains a larger promoter fragment upstream of a smaller
G-free cassette. These templateswere transcribed using equal
quantities of nuclear extract from control (C) and TSA-
treated (T) cells as shown in Figure 4(c).W h i l et r a n s c r i p t i o n
from the AdML template was similar in the two extracts,
MMTV transcription was reduced in the extracts from
TSA-treated cells. To eliminate the possibility that these
results were due to diﬀerences in transcriptional competency
speciﬁc to a particular set of extracts, we generated two
additional sets of extracts (control and TSA-treated) and
performed the same experiment. Figure 4(d) shows that
the patterns of transcription from the two templates are
very reproducible. MMTV transcription was consistently
reduced in extracts from TSA-treated cells relative to a6 Journal of Biomedicine and Biotechnology
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Figure 2: Transcription dependent on core promoters is repressed by TSA. Luciferase reporter constructs were generated which contain
core promoters (TATA to Inr sequences) from several viral and cellular genes, including Cytomegalovirus (CMV), c-fos, interleukin 4 (IL4),
and carbonic anhydrase II (CA2). These constructs were transiently transfected into either Hela or 1470.2 cells which were treated with or
without TSA (50ng/ml) for 6h. Cell lysates were assayed for luciferase activity, and the data was processed as described in the legend to
Figure 1. Results from at least 3 independent experiments done with Hela or 1470.2 cells are shown. Error bars represent SEM.
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Figure3:InhibitionofHDACsresultsinthelossofinitiatingRNApolIIfromtheMMTVpromoter.1470.2cellsweretreated witheitherDex
(100nM)orTSA(50ng/ml)for0,15,30,or60minutes,afterwhichcells wereprocessedforChIPassay.Chromatinwasimmunoprecipitated
with an RNA pol II antibody that recognizes the hypophosphorylated form of the CTD. Conventional PCR was performed on input and
immunoprecipitated DNA using primers speciﬁc for the MMTV promoter and the coding region (CDS) of the CAT reporter. PCR results
from a representative experiment are shown in (a). A graphical representation of the data from 2 to 3 independent experiments is shown
in (b) for the TSA time course. Values from control samples were set to 1, and values from TSA-treated samples are expressed as a fraction.
Error bars represent SEM.
matched control extract while AdML transcription was
unaﬀected. We therefore conclude that the repression of
MMTV transcription we observe in cell-based assays is
recapitulated in vitro, and that this system can be utilized to
ask precise mechanistic questions about the role of HDAC
activity in transcriptional initiation.
3.4. Transcriptional Reinitiation Rather Than De Novo
Transcription Is Sensitive to HDAC Inhibition. Transcrip-
tionalinitiationisabroadtermthatincorporatestwodistinct
processes:denovotranscription, whichistheinitialassembly
of a preinitiation complex (PIC) and the ﬁrst round of
transcription, and reinitiation, which is the recruitment
of RNA pol II to a pre-existing scaﬀold complex that is
distinct in composition from the PIC. De novo transcription
can be diﬀerentiated from reinitiation with the use of the
detergent sarkosyl [37, 38]. If added to a preassembled PIC
prior to the addition of nucleotide triphosphates (NTPs),
sarkosyl (0.05%) will inhibit all transcription as shown for
the AdML template in Figure 5(a). However, if it is added
several seconds after NTP addition, the initial round of
transcription will proceed and reinitiation is inhibited. As
seen in Figure 5(a), this results in a signiﬁcantly lower
amount of transcript because only de novo transcription
occurs. To determine whether HDAC activity is involvedJournal of Biomedicine and Biotechnology 7
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Figure 4: Repression of MMTV transcription by TSA is consistently recapitulated in an in vitro transcription assay. (a) Flow chart for
a typical experiment. Nuclear extracts are generated from Hela S3 cells which were either untreated or TSA treated. These extracts were
used for in vitro transcription assays with the templates shown in (b). The MMTV template contains the region from the TATA box to the
initiator element and a G-free cassette of 400bp. The adenovirus major late (AdML) template contains a promoter fragment from −400bp
to +10bp with a G-free cassette of 190bp. Results of a typical transcription assayare shown in (c). C-extract from untreated cells (Control).
T-extract from TSA-treated cells. (d) shows a graphic representation of assay results using three independent sets of extracts. Each extract
was assayed with each template at least three times. Transcription levels in the extracts from TSA-treated cells are expressed relative to those
in the corresponding extracts from untreated (control) cells.
in regulation of these distinct initiation processes at the
MMTV core promoter, we ﬁrst established the extent to
whichreinitiationoccursinourinvitrotranscriptionsystem.
The MMTV orAdMLtemplateswere incubatedwith nuclear
extractsfromuntreated cellstoallowdenovoassembly ofthe
PIC. Nucleotide triphosphates (NTPs) were added to initiate
transcription. After 30 seconds, sarkosyl or water was added
and transcription was allowed to proceed for 1h. As shown
in Figure 5(b), about 90% of the transcription product from
both templates is due to reinitiation since levels of transcript
from each template in the presence of 0.05% sarkosyl were
only 10% of those measured in its absence.
To determine whether HDAC inhibition impairs de
novo transcription, the levels of MMTV transcript were
measured after transcription in extracts from both control
and TSA-treated cells in the presence or absence of sarkosyl.
In Figure 5(c), transcript levelsare expressed relative to those
measured in control extracts in the absence of sarkosyl. As8 Journal of Biomedicine and Biotechnology
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Figure 5: HDAC inhibition by TSA impairs reinitiation of transcription from the MMTV promoter in vitro. (a) In vitro transcription was
carried out with the AdML template. Nuclear extracts were mixed with the template, and PIC assembly was allowed to proceed for 1h.
Sarkosyl was added either 2 minutes before or 10 seconds after NTP addition. Transcription was allowed to proceed for 1h. (b) In vitro
transcription was carried out in the presence or absence of sarkosyl (0.05%) added after NTP addition using either the MMTV or AdML
templates as described in Section 2. Transcription levels in the presence of sarkosyl are expressed relative to levels of transcription measured
in the absence of sarkosyl. (c, d) Transcription of the MMTV template was carried out using extracts from either control or TSA-treated
cells in the presence or absence of sarkosyl (0.05%). In (c), transcription levels are expressed relative to those measured in control extracts
in the absence of sarkosyl. In (d), transcription levels measured in extracts from TSA-treated cells are expressed relative to those measured
in control extracts, both in the presence of sarkosyl. The results shown were obtained from three independent experiments, and error bars
represent SEM.
expected, transcription of the MMTV template is reduced
in extracts from TSA-treated cells in the absence of sarkosyl.
However, in the presence of sarkosyl, transcript levels are
similar in the two extracts. In Figure 5(d),t r a n s c r i p tl e v e l s
produced in the extracts from TSA-treated cells in the
presence of sarkosyl are expressed relative to those measured
in the control extracts under the same conditions to conﬁrm
that there is no signiﬁcant diﬀerence. These results show
that de novo transcription is unaﬀected by the lack of HDAC
activity and strongly suggest that the reduction in MMTV
transcription in the extracts derived from TSA-treated cells
is due to impaired reinitiation.
3.5. Initiation Complex Stability and HDAC Inhibition.
Two potential mechanisms by which HDAC activity
might regulate transcriptional reinitiation include (1) the
destabilization and dissociation of the reinitiation scaﬀold
in the absence of HDAC activity and (2) inhibition of the
activity of the scaﬀold and/or its ability to recruit RNA pol
II. To distinguish between these possibilities, we performedJournal of Biomedicine and Biotechnology 9
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Figure 6: HDAC inhibition does not aﬀect the stability of initiation complexes at the MMTV promoter as determined by template
competition assay. Transcription of the MMTV template in extracts from control or TSA-treated cells was carried out in the presence of
increasing amounts of AdML template. A representative experiment is shown in (a). (b) shows the relative level of MMTV transcription in
extracts from eithercontrol orTSA-treated cells. Transcriptionallevels ineach extract are expressed relative to thosemeasuredin the absence
of AdML template. The results shown are derived from at least 3 independent experi
ments. The data were subjected to linear regression analysisto generate lines and slopes using GraphPad Prism. Error bars represent SEM.
template competition assays in which transcription from
a ﬁxed amount of MMTV template was carried out in the
presence of increasing amounts of the AdML template as
a competitor. As the amount of AdML DNA increases,
transcription from the MMTV promoter should decrease.
T h i sc a nb eo b s e r v e di nF i g u r e6(a), lanes 1–5, and lanes
6–10 for transcription carried out in extracts from control
and TSA-treated cells, respectively. The relationship between
MMTV transcript levels and AdML template for each extract
was then analyzed by linear regression to generate a line
as shown graphically in Figure 6(b). If the lack of HDAC
activity results in major destabilization of the reinitiation
scaﬀold,theslope oftheline depicting transcript levelsin the
extracts from TSA-treated cells would be signiﬁcantly higher
(steeper line) because the AdML template would compete
more eﬀectively for factors. However, the data shows that
the slopes of the two lines are not signiﬁcantly diﬀerent
even though the level of overall MMTV transcription in
the extracts from TSA-treated cells is lower (shown in
Figure 6(a)). This result suggests that the loss of HDAC
activity does not aﬀect the overall stability of the reinitiation
scaﬀold but rather decreases its activity.
3.6. HDAC Activity Is Not Required during the Transcription
Process. HDAC activity might regulate the eﬃciency of
reinitiation either by being directly required during the
process of transcriptional initiation or by regulating the
activity of components of the reinitiation scaﬀold. In the
case of the former, a critical deacetylation reaction may
take place with every round of initiation, analogous to the
way the CTD of RNA pol II must be dephosphorylated
before it can reinitiate transcription. Alternatively, HDACs
regulate the activity of a scaﬀold component, perhaps
through its acetylation status. Treatment of cells with HDAC
inhibitors prior to generation of nuclear extracts would lead
to the accumulation of this component in its functionally
impaired state. This accumulation would thereby increase
the chances of assembling functionally impaired scaﬀold
complexes.
To distinguish between these possibilities, we asked
whether TSA added to extracts from untreated control cells
could inhibit MMTV transcription according to the scheme
outlined in Figure 7(a). If HDAC action was required during
each round of transcription, wee x p e c tt h a tt r a n s c r i p t i o n
would be inhibited by the addition of TSA to the control
extract. To establish that the added TSA inhibits HDAC
activity, an HDAC assay was performed to compare control
extracts to which either TSA or DMSO had been added.
As shown in Figure 7(b), HDAC activity is signiﬁcantly
inhibited by addition of TSA to a level even lower than
that measured in extracts generated from cells treated with
TSA. In vitro transcription was carried out on the MMTV
templates using either extracts generated from cells treated
with or without TSA or with the control extract to which
TSA or the vehicle, DMSO, had been added. Consistent with
previous experiments, MMTV transcription was reduced
in extract from cells treated with TSA relative to control
extracts. However, the additionofTSAdirectly to the control
extractdidnotimpairMMTV transcription. Thisresultindi-
cates that HDAC activity is not directly required during the
initiation and elongation process and suggests that impaired
function of the assembled basal transcription machinery
is responsible for the reduced rate of transcriptional
initiation.10 Journal of Biomedicine and Biotechnology
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Figure 7: HDAC activity is not required during transcription of the MMTV promoter. (a) showsthe experimental outline. Vehicle (DMSO)
or TSA (50ng/ml) was added to extracts from untreated (control) cells. These extracts were then subjected to HDAC assay or used for in
vitro transcription. (b) shows the results of HDAC assays on control extracts to which vehicle or TSA had been added. The same assay was
performed on extracts from cells treated with TSA as a comparison. The graph represents data from 3 independent experiments. (c) shows
the results of in vitro transcription from the MMTV template comparing extracts from cells treated with or without TSA (Cell treated) with
extracts from untreated (control) cells to which vehicle or TSA had been added (NE treated). The graph was generated from data derived
from at least 3 independent experiments. Error bars represent SEM.
4.Discussion
Despite accumulating evidence that HDACs and protein
deacetylation play positive roles in regulation of transcrip-
tion, virtually nothing is known about the underlying
mechanisms. In our previous study, we established that
inhibition of HDAC activity caused repression of MMTV
promoter activity that was transcriptional in nature and
independent of changes in histone acetylation, chromatin
structure, chromatin remodeling, and the binding of tran-
scription factors upstream from the TATA box. In the
current study, we have investigated the mechanisms behind
this repression and found that it is mediated through the
functional core promoter elements of the MMTV LTR and
can also be observed with the core promoters of other
genes. In addition, this repression is due to the inhibition
of transcriptional initiation and correlates with decreased
associationofRNApolIIwiththepromoter.Developmentof
an in vitro transcription system that recapitulates repression
due to HDAC inhibition has allowed us to determine that
reinitiation rather than de novo transcriptional initiation is
sensitivetoHDACinhibition.Theimpairmentofreinitiation
is not due to wholesale destabilization of the scaﬀold
complex or a requirement for HDAC activity during each
round of initiation, but rather, the results indicate that
the ability of the assembled scaﬀold to recruit RNA pol
II is inhibited. This study extends our knowledge of the
transcriptional roles of HDACs and provides novel insights
into the role of HDACs in facilitating transcription through
t h ec o r ep r o m o t e ra n db a s a lt r a n s c r i p t i o nm a c h i n e r y .
Analysis of MMTV sequences necessary to confer repres-
sion on transcription through HDAC inhibition revealed its
surprising dependence on the core promoter. The analogous
region from several other genes displayed similar behavior.
Interestingly, repression of both promoters of the c-src gene
by HDAC inhibitors was found to be mediated through their
core promoter regions [39, 40] .T h ec o r ep r o m o t e ri so f t e n
viewed, not as an active participant in gene regulation, but
only as a place to assemble the basal transcription machinery
in response to the action of transcription factors bound
to the promoter or distant enhancers. However, core pro-
moter elements are not uniform between genes but usually
occur in subsets (e.g., TATA/Inr, Inr/DPE, BRE/TATA/DPE)
(reviewed in [30]). In addition, some transcriptional activa-
tors work more eﬃciently with a particular core promoter
subtype, such as Caudal, a key regulator of Hox genes, whichJournal of Biomedicine and Biotechnology 11
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Figure 8: Proposed model for the role of HDACs in basal
transcription from the MMTV promoter. (a) HDACs remove acetyl
groups from proteins that are part of the reinitiation scaﬀold. This
may occur prior to binding to the template (as shown) or at the
template. This deacetylation facilitates binding of RNA pol II and
the initiation of transcription. When HDAC activity is inhibited
through HDAC inhibitors, shown in (b) persistent acetylation of
basal transcription machinery components does not destabilize the
complex or prevent its assembly. However, the recruitment of RNA
polII is impaired, leadingto a decrease inthe rateoftranscriptional
initiation.
prefers core promoters with a DPE to those with a TATA box
[41, 42]. Such examples imply that the basal transcription
complexes that form at these diﬀerent core promoters diﬀer
somewhat in conﬁguration, stability, or composition and
therefore may respond distinctly to regulatory signals.
All the core promoters tested in our study contain both a
TATA box and Inr element; some also contain an upstream
BRE (CMV and CA2). Our results would seem to imply
that all genes with TATA/Inr-containing core promoters are
repressed by HDAC inhibitors, but we showed this not to
be the case in our previous study [22]. We suggest that
when transcription is strictly dependent on this type of
core promoter, there is a requirement for HDAC activity.
However, in the context of the other regulatory regions that
control the expression of a particular gene, the combination
of transcriptional regulators that bind to them can overcome
this requirement. For promoters such as MMTV, the tran-
scriptional regulators that bind upstream of the TATA box
are unable to overcome the repression of basal transcription
caused by the loss of HDAC activity. The gene speciﬁcity of
t h ec o r ep r o m o t e rr e q u i r e m e n tf o rH D A Ca c t i v i t ym a yb e
mediated by dependence of key transcriptional regulators on
diﬀerent components of the basal transcription complexes
to facilitate transcriptional initiation. Some subunits of the
Mediatorand TFIIDcomplexeshavebeen shown to function
in a gene-speciﬁc fashion and/or to be diﬀerentially utilized
by promoter-bound transcription factors (reviewed in [43,
44]). For example, the ligand-dependent nuclear receptors
havebeenshown torequirethepresenceof theMed1subunit
of the mediator complex to activate some target promoters,
and the estrogen receptor (ER) has been shown to contact
TAF10 of TFIID to activate transcription [45]. Interestingly,
GR has been reported to require diﬀerent mediator subunits
in distinct promoter contexts [46, 47]. Posttranslational
modiﬁcation (such as acetylation) of complex subunits
required for interaction with particular transcription factors
may disrupt those interactions and lead to a reduction in
activated or basal transcription. Alternatively,atranscription
factor bound to a gene may bypass the negative eﬀects of
a functionally impaired subunit of the basal transcription
machinery if it requires other subunits to facilitate transcrip-
tion. In the case of MMTV, we propose that the upstream
factors that drive transcription require the function of the
impaired subunit(s) that causes repression of core promoter
activity and therefore cannot overcome the loss of HDAC
activity.
Our experiments with sarkosyl show that de novo
transcriptional initiation from the MMTV promoter is unaf-
fected by HDAC inhibition, indicating that the repression
observed is due to impaired reinitiation. De novo initiation
involves the assembly of the PIC at a completely inactivate
promoter. Once the original round of transcription has
begun and the polymerase leaves the core promoter, a
scaﬀold is left behind which contains general transcription
factors TFIID, -IIA, -IIH, -IIE, and the mediator complex
[48]. Some transcription factors stabilize this scaﬀold and
facilitate transcription by increasing the rate of reinitiation
[48–51].InastudyoftheeﬀectsofTSAonHIVtranscription
in vitro, it was observed that TSA increased the amount
of de novo transcription [51]. These experiments were
performed with chromatin-assembled HIV templates, and
the stimulatory eﬀect of TSA on de novo transcription may
have been due to increased histone acetylation, which has
been shown to facilitate interactions between transcription
factors and chromatin (reviewed in [52] ) .T h es a m es t u d y
also showed that TSA had little eﬀect on reinitiation of HIV
transcription [51]. However, it was also determined that the
transcription factors which bind the HIV promoter were
highly eﬃcient in stimulating reinitiation in vitro. As we
discussed above, it is certainly possible that this combination
of factors can overcome any negative eﬀects of acetylation
on reinitiation in the HIV promoter context. Our studies
of the MMTV promoter strongly suggest that this is not
true of the combination of transcription factors that control
its transcriptional activity. However, the speciﬁc eﬀects of
HDAC inhibition on reinitiation versus de novo initiation
provides a potential explanation for the ability of GR to
partially activate the MMTV promoter in the presence of
TSA or HDAC1 depletion [17, 22]. There is a level of basal
MMTV transcription in our cell lines, which is likely to be
due to either stochastic de novo assembly of the PIC and/or a
low rate of reinitiation from pre-existing scaﬀold complexes.
GR may act to both promote de novo assembly of the PIC
at MMTV templates within a cell population and increase
reinitiation at preassembled scaﬀold complexes. Our results12 Journal of Biomedicine and Biotechnology
suggest that GR-induced de novo transcription within a cell
population would not be aﬀected by loss of HDAC activity
but that reinitiation would be impaired, thus decreasing the
magnitude of GR-activated MMTV transcription but not
completely inhibiting it.
Why would HDAC activity and deacetylation aﬀect only
reinitiation and not de novo transcription? A recent study
indicates that the structure of the reinitiation scaﬀold is
distinct from that of the initial PIC. Knuesel and colleagues
showed that the Cdk8 submodule of the mediator can
bind to the reinitiation scaﬀold but not the initial PIC
[53]. Once bound, it can repress the rate of reinitiation
because RNA pol II cannot rebind. They hypothesize that
there is a structural shift in mediator structure that occurs
once pol II has cleared the initial PIC which allows this
module to bind and act as a rheostat. It is also possible
that conformational changes occur in other components of
the basal transcription machinery after the initial round of
transcription. A diﬀerence between the initial PIC and the
reinitiationscaﬀoldmayalsoexplainthediﬀerentialabilityof
transcription factors to facilitate reinitiation [48]. Our study
has elucidated another key diﬀerence between reinitiation
and de novo transcription and that is a requirement for
HDAC activity.
How does HDAC activity aﬀect reinitiation? The tem-
plate competition experiments indicate that HDAC activity
does not stabilize the reinitiation scaﬀold since the ability of
the AdML template to compete with MMTV for complex
assembly was not increased in extracts from TSA-treated
cells.This ﬁnding implies thatitis theactivity ratherthan the
overall stability of the scaﬀold that is impaired when HDAC
activity is compromised. The ChIP experiments showed that
TSA treatment resulted in decreased association of RNA
pol II with the MMTV promoter. Thus, it is possible that
the ability of the reinitiation scaﬀold to recruit pol II is
dependentonHDACactivityasshowninthemodeldepicted
in Figure 8. However, inhibition of HDACs through addition
of TSA to the control nuclear extracts did not lead to
inhibition of MMTV transcription, meaning that HDAC
activity is not required during the process of reinitiation,
perhaps removing acetyl groups that were acquired during
initiation and must be removed prior to binding of another
pol II complex, analogous to the phosphorylation cycles of
the pol II CTD [34].
We hypothesize that treatment of cells with TSA prior
to generation of the nuclear extracts led to changes in the
acetylation status of one or several proteins that regulate
transcriptional initiation. This regulation could be indirect,
involving HDAC target proteins that inﬂuence the activity
or post-translational modiﬁcation of the basal transcription
machinery but are not directly involved in transcriptional
initiation at the core promoter. However, we argue that the
eﬀect of acetylation on transcriptional initiation is more
direct. First, nuclear run-on experiments in our previous
study clearly showed that basal transcription from the
MMTV promoter decreases immediately, within 5 minutes
of TSA treatment [22]. A delay might be expected if an
indirect mechanism was in play. Second, it has been shown
thatHDAC1isconstitutivelypresentat theMMTV promoter
and that its depletion by RNA interference impairs MMTV
transcription [17]. A change in its activity by exposure to
HDAC inhibitors could immediately aﬀect the dynamics of
acetylation at the promoter to cause a rapid decrease in
transcription through increased acetylation ofproteinsatthe
promoter. These proteins couldbe subunits ofthe complexes
that make up the reinitiation scaﬀold or proteins known to
directly regulate basal transcription such as NC2, BTAF, or
the Cdk8 module of the mediator complex (reviewed in [43,
54]). Loss of HDAC activity would increase the acetylated
fraction of these proteins, thereby increasing the chance that
acetylated forms were incorporated into PICs and scaﬀolds
formed at our templates in vitro. HAT activity in the nuclear
extracts may not have been robust enough or targeted
enough to signiﬁcantly increase acetylation of these proteins
when HDACs were inhibited in vitro (Figure 7). In spite of
the fact that TFIID contains an acetyltransferase (TAF1) and
robust HATs such as CBP, p300, and PCAF are recruited to
many promoters, very littleis known aboutacetylation ofthe
basal transcription machinery, including whether there are
acetylated subunits, and if so, how acetylation aﬀects their
function.
Insummary, ourstudyhasuncoveredanovelmechanism
by which HDACs function in facilitating transcriptional
initiation. Future studies will be directed at identifying
the critical target of HDAC activity that regulates basal
transcription and further dissection of the mechanism by
which HDAC activity impacts reinitiation.
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